Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D financing gives TargeGen $40mm

Executive Summary

TargeGen (developing small molecules for vascular function diseases such as macular degeneration) closed a fully subscribed $40mm Series D round. First-time backers Innovis Investments, VantagePoint Venture Partners, and CTI Life Sciences Fund were joined by returning investors including Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, CDP Capital, BB Biotech, Hambrecht & Quist Capital Management, and Pappas Ventures. The company added an executive from Innovis to its board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies